🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#PSMAfore analysis: In taxane-naive mCRPC, C2D1 ctDNA fraction was linked to rPFS & OS vs. baseline ctDNA. Early ctDNA drop predicted outcomes beyond PSA alone in Lu-PSMA-617-treated pts. #JohannSDeBono #KimNChi ASCO #GU25 OncLive.com OncoAlert

Very comprehensive multidisciplinary panel on the management of BCR after RT for localized #prostatecancer featuring our very own Alicia Morgans, MD, MPH from Dana-Farber, #JuanitaCrook from University of British Columbia, #AshleyRoss from Northwestern, and Thomas Polascik from DCI Center for Prostate & Urologic Cancers. Moderated by

Many institutions disallow or limit ICIs for hospitalized pts w/cancer because they have to eat the cost. But what about clinical benefits? Our group examined clinical outcomes of pts treated with inpatient ICIs at 5 large academic institutions. ascopubs.org/doi/10.1200/OP…

Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC. ASCO #GU25 Robert Motzer MD Tom Powles Memorial Sloan Kettering Cancer Center OncoAlert

🚨#IMG physician parents👉Don't forget to take this 5-min survey! 🔗tinyurl.com/muy8t3am OncoAlert Hem-Onc Fellows Network

Our new paper in Journal for ImmunoTherapy of Cancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e… Rafeh Naqash, MD Amin Nassar, MD Sarah Abou Alaiwi Talal El Zarif, MD Rana McKay, MD, FASCO Dana-Farber

‼️Only data so far of ICI in pts with cardiac Mets. Work led by Amin Nassar, MD Sarah Abou Alaiwi Talal El Zarif, MD out in Journal for ImmunoTherapy of Cancer . A collaboration that spanned several countries and centers. OU College of Medicine OU Health Stephenson Cancer Center Toni Choueiri, MD jitc.bmj.com/content/13/3/e…

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC buff.ly/iFnRFbO This retrospective, multicenter study examined the safety and clinical outcomes of 110

🚨Save the date🚨 ASCO #IMG Community of Practice Meeting at #ASCO25 ⏰May 30st, 4-6 PM CST 📌Room S103, McCormick Place Join us to discuss barriers & opportunities for IMGs ASCO IMG CoP👉bit.ly/3JmJQwK The ASCO Post #IMGoncCoP #MedEd #MedTwitter

This may be the most discussed abstract ASCO. Much talk about ivermectin as treatment for cancer, esp on social media. But what are the data? To my knowledge, there are no actual clinical trial data - until now. The New York Times The Wall Street Journal FORTUNE OncoAlert LARVOL

My personal selection of the high yield abstracts for melanoma that will be presented at ASCO 2025! ASCO #ASCO25

🔔Make sure to check our study!! ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS

#ASCO25 #melanomaorals RELATIVITY-098 showed no RFS benefit in the adjuvant setting of Opdualag for high risk resected stage 3 melanoma, adjuvant PD-1 therapy remains the standard for this patient population

#ASCO25 #melanomaorals Adjuvant therapy with Encorafenib (BRAFi) with Binimetinib (MEKi) for high risk resected stage 2B and 2C melanoma could be a potential effective therapy with the known safety profile of this drug combination

#ASCO25 #melanomaorals A single dose of Neoadjuvant Pembro for clinical stage 2B and 2C was safe and did not delay surgery, all while it could have a decreased rate of positive SLNBs for some stage 2C melanomas with a potential benefit in RFS and DFMS

#ASCO25 #melanomaorals Multiple neoadjuvant combination therapies are being explored for high risk resectable stage 3 melanoma, certainly an evolving field! Excited to see how we can bring more effective therapies in this setting to benefit all of our patients!

#ASCO25 #melanomaorals DREAM-Seq continues to show significant clinical benefit for stage 4 patients with BRAF-mutant melanoma that are treated with upfront Ipi/Nivo vs BRAF/MEK inhibitors, continuing to show IO as the standard for first line systemic therapy

#ASCO25 #melanomaorals Upfront Encorafenib/Binimetinib with Nivo has a PFS benefit compared to Ipi/Nivo for patients with symptomatic BRAF mutant metastatic melanoma with Brain mets. No significant differences in OS

#ASCO25 #melanomaorals 1 year versus 2 years of PD-1 therapy continues to be an important question to answer for our stage 4 patients with melanoma that achieve a response and remain on therapy. Data shared hear looks encouraging though the study was underpowered

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in Nature Cancer MarleenKokLab doi.org/10.1038/s43018…